Granzyme B Antibody, anti-human/mouse/rat, REAfinity™
Synonyms: GZMB, CCPI, CGL-1, CSP-B, CTLA-1, CTSGL1, HLP, SECT, Granzyme 2
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
110 Citations11 Images
Clone:
REA226 | GB11
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for Granzyme B Antibody, anti-human/mouse/rat, REAfinity™

Intracellular flow cytometry applications
APC
FITC
PE
PE-Vio 670
Vio B515
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-120-703, 130-120-773
Description:
Human peripheral blood mononuclear cells (PBMCs) were stimulated or either left unstimulated (left image) with CD3 and CD28 for 3 days followed by an incubation with 1µg/mL Brefeldin A and Monensin for 6 hours. Cells were then stained with Anti-Granzyme B antibodies, as well as with CD8 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-108-055
Reported:
Extended validation for Granzyme B Antibody, anti-human/mouse/rat, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA226
GB11
++
QA16A02
partial

Cells were incubated with an excess of purified unconjugated Granzyme B (REA226) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for Granzyme B. Human peripheral blood mononuclear cells (PBMCs) were stained with a suitable counterstaining. Cells were then fixed and permeabilized followed by a staining with Granzyme B. As a control, Granzyme B antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for Granzyme B Antibody, anti-human/mouse/rat, REAfinity™
Overview

Clone REA226 recognizes granzyme B, a 32 kDa member of serine protease family, which is involved in cell lysis mediated by cytotoxic T lymphocytes (CTLs) and NK cells. Also known as granule enzymes, granzymes comprise majority of the mass of cytolytic granules in cytotoxic T lymphocytes (CTLs) and NK cells. Granzyme B is one of the five granzymes expressed by humans. NK cells and γδ T cells express granzymes constitutively, whereas expression in T lymphocytes is stimulation dependent. Main function attributed to granzymes is to indue apoptotic death of infected and transformed cells, where granzyme B enters into the target cell in a perforin dependent manner and via cation-independent mannose-6-phosphate receptor (CI-MPR). Granzyme B cleaves cellular substrates such as procaspase-3 and Bid, which then initiate pathways involved in apoptotic cell death. Granzyme B is suggested to be the only mammalian serine protease that prefers acidic side chains.

Additional information: Clone REA226 displays negligible binding to Fc receptors.

Alternative names

GZMB, CCPI, CGL-1, CSP-B, CTLA-1, CTSGL1, HLP, SECT, Granzyme 2

Detailed product information

Technical specifications

Clone
REA226
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, rat
Antigen
Granzyme B
Distribution of antigen
T cells, NK cells
Entrez Gene ID
RRID
AB_2922311, AB_2922317, AB_2784341, AB_2733664, AB_2659980, AB_2733663, AB_2727564, AB_2727639, AB_2784340

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for Granzyme B Antibody, anti-human/mouse/rat, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?